Si-Bone Inc (SIBN)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Si-Bone Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 17.80 $ — 63% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Analysts & Price Target
The price target sits 37.3% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.42 | -0.50 – -0.37 | 232 | 3.8% | 8 |
| 12/31/2027 | -0.34 | -0.43 – -0.24 | 268 | 18.9% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.15 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.11 | – | 49 | 26.10 | -9.20 | 1 | -1 |
| 2025: Q1 | -0.15 | – | 47 | 24.90 | -13.80 | -5 | -7 |
| 2025: Q2 | -0.14 | – | 49 | 21.70 | -12.70 | 0 | -2 |
| 2025: Q3 | -0.11 | – | 49 | 20.60 | -9.40 | 2 | -1 |
| 2025: Q4 | -0.04 | – | 56 | 15.00 | -2.90 | 2 | 0 |
| 2026: Q1 | -0.10 | – | 53 | 11.20 | -8.20 | -2 | -3 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 42 | -18 | -21 | -1.33 | -17 | -109 | 39 |
| 2017 | 48 | -17 | -23 | -1.66 | -18 | -129 | 36 |
| 2018 | 55 | -12 | -17 | -1.10 | -15 | 90 | 139 |
| 2019 | 67 | -36 | -38 | -1.55 | -32 | 63 | 117 |
| 2020 | 73 | -39 | -44 | -1.50 | -31 | 169 | 223 |
| 2021 | 90 | -52 | -57 | -1.71 | -40 | 134 | 191 |
| 2022 | 106 | -60 | -61 | -1.79 | -42 | 98 | 158 |
| 2023 | 139 | -47 | -43 | -1.13 | -19 | 169 | 230 |
| 2024 | 167 | -35 | -31 | -0.75 | -12 | 167 | 230 |
| 2025 | 201 | -22 | -19 | -0.43 | -1 | 178 | 239 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
SI-BONE, Inc., ein Medizinprodukteunternehmen, entwickelt verfahrenstechnische Lösungen für geschwächte Knochen, gestützt auf Expertise in biomechanischem Design und anatomiespezifischen Anwendungen, in den USA und international.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 376 |
| Headquarters | Santa Clara, CA |
| Address | 471 El Camino Real, 95050 Santa Clara, United States |
| Phone | 408 207 0700 |
| Website | si-bone.com |
| IPO Date | 17. Oct 2018 |
| ISIN | US8257041090 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jeffrey W. Dunn | Executive Chairman | 1956 |
| Laura A. Francis MBA | CEO & Director | 1967 |
| Anshul Maheshwari | COO & CFO | 1980 |
| Michael A. Pisetsky J.D. | Chief Business & Legal Affairs Officer, Secretary and General Counsel | 1978 |
| Anthony J. Recupero | Advisor | 1960 |
| Scott A. Yerby Ph.D. | Senior VP of Engineering & CTO | 1968 |
| Saqib Iqbal | Vice President of Financial Planning & Analysis and Investor Relations | – |
| Ian Bailey | Vice President of Product & Marketing | – |
| Daniel Joseph Cher M.D. | Senior Vice President of Clinical, Regulatory Affairs & Quality | 1965 |
| W. Carlton Reckling M.D. | Chief Medical Officer & VP of Medical Affairs | 1963 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.